Gray Zone Lymphoma

• CLINICAL_TRIALS trial_result · 2025-11-26
  Clinical Trial Update: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma [Phase 1]

  This Phase 1 trial examined lenalidomide combined with blinatumomab for relapsed non-Hodgkin lymphoma across multiple subtypes and has compl…

• CLINICAL_TRIALS trial_result · 2025-06-12
  Clinical Trial Update: Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma [Phase 2]

  Phase 2 trial evaluating dose-adjusted EPOCH chemotherapy plus Rituximab in previously untreated aggressive non-Hodgkin lymphoma has complet…

• CLINICAL_TRIALS trial_result · 2023-11-28
  Clinical Trial Update: Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas [Phase 2]

  Phase 2 trial of pembrolizumab in relapsed/refractory gray-zone lymphoma, primary CNS lymphoma, and other extranodal diffuse large B-cell ly…

• CLINICAL_TRIALS trial_result · 2021-04-27
  Clinical Trial Update: A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma [Phase 2]

  A Phase 2 trial evaluating PD-1 inhibitor combined with ICE chemotherapy for relapsed/refractory Gray Zone Lymphoma.

• CLINICAL_TRIALS trial_result · 2019-09-17
  Clinical Trial Update: Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients [Phase 1, Phase 2]

  Phase 1/2 study evaluating brentuximab vedotin with chemotherapy in CD30+ primary mediastinal large B-cell lymphoma, CD30+ diffuse large B-c…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2018-12-26
  Clinical Trial Update: Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma [Phase 2]

  Phase 2 trial assessing maintenance rituximab combined with mTOR inhibition after high-dose consolidative therapy in various B-cell lymphoma…